Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 58.98
-1.68 (-2.77%)
Sep 29, 2025, 2:46 PM CST
SHE:002294 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 3,983 | 3,910 | 3,280 | 3,401 | 3,020 | 2,731 | Upgrade |
Other Revenue | 117.54 | 102.73 | 85.67 | 81.27 | 38.73 | 7.07 | Upgrade |
| 4,101 | 4,012 | 3,365 | 3,482 | 3,058 | 2,739 | Upgrade | |
Revenue Growth (YoY) | 10.12% | 19.22% | -3.35% | 13.85% | 11.68% | -38.74% | Upgrade |
Cost of Revenue | 1,063 | 1,138 | 1,065 | 1,001 | 811.29 | 847.87 | Upgrade |
Gross Profit | 3,037 | 2,874 | 2,300 | 2,481 | 2,247 | 1,891 | Upgrade |
Selling, General & Admin | 1,846 | 1,745 | 1,302 | 1,332 | 1,340 | 1,187 | Upgrade |
Research & Development | 454.23 | 421.24 | 409.19 | 533.75 | 357.37 | 371.2 | Upgrade |
Other Operating Expenses | 43.76 | 18.76 | 20.2 | 46.93 | 44.98 | 34.67 | Upgrade |
Operating Expenses | 2,356 | 2,190 | 1,734 | 1,916 | 1,743 | 1,584 | Upgrade |
Operating Income | 680.87 | 683.93 | 565.82 | 565.58 | 504.3 | 306.3 | Upgrade |
Interest Expense | -17.66 | -16.17 | -17.37 | -12.54 | -10.53 | -17.57 | Upgrade |
Interest & Investment Income | 87.11 | 80.09 | 80.94 | 151.26 | 181.9 | 35.5 | Upgrade |
Currency Exchange Gain (Loss) | -2.89 | 1.69 | 3.01 | 5.55 | -5.78 | -5.35 | Upgrade |
Other Non Operating Income (Expenses) | 4.06 | -1.37 | -0.43 | -5.84 | -7.54 | -21.46 | Upgrade |
EBT Excluding Unusual Items | 751.49 | 748.17 | 631.96 | 704 | 662.35 | 297.43 | Upgrade |
Impairment of Goodwill | - | - | -49.61 | -26.61 | - | -282.72 | Upgrade |
Gain (Loss) on Sale of Investments | 14.86 | 14.51 | 8.09 | 3.81 | - | -26.78 | Upgrade |
Gain (Loss) on Sale of Assets | -1.11 | -0.15 | -0.48 | -0.18 | -1.3 | 0.21 | Upgrade |
Asset Writedown | -159.46 | -159.64 | -2.89 | -24.06 | -131.6 | -1.59 | Upgrade |
Other Unusual Items | 46.5 | 29.62 | 54.68 | 56.76 | 70.39 | 70.21 | Upgrade |
Pretax Income | 652.28 | 632.52 | 641.76 | 713.73 | 599.84 | 56.74 | Upgrade |
Income Tax Expense | 16.05 | 27.36 | 60.93 | 79.36 | 71.52 | 6.61 | Upgrade |
Earnings From Continuing Operations | 636.23 | 605.16 | 580.83 | 634.37 | 528.32 | 50.13 | Upgrade |
Minority Interest in Earnings | -13.67 | -3.59 | -0.76 | 2.73 | 5.41 | 10.73 | Upgrade |
Net Income | 622.56 | 601.57 | 580.07 | 637.09 | 533.73 | 60.86 | Upgrade |
Net Income to Common | 622.56 | 601.57 | 580.07 | 637.09 | 533.73 | 60.86 | Upgrade |
Net Income Growth | 6.14% | 3.71% | -8.95% | 19.37% | 776.90% | -91.49% | Upgrade |
Shares Outstanding (Basic) | 1,112 | 1,114 | 1,116 | 1,098 | 1,067 | 1,014 | Upgrade |
Shares Outstanding (Diluted) | 1,112 | 1,114 | 1,116 | 1,098 | 1,067 | 1,014 | Upgrade |
Shares Change (YoY) | 0.40% | -0.13% | 1.55% | 2.90% | 5.23% | -3.55% | Upgrade |
EPS (Basic) | 0.56 | 0.54 | 0.52 | 0.58 | 0.50 | 0.06 | Upgrade |
EPS (Diluted) | 0.56 | 0.54 | 0.52 | 0.58 | 0.50 | 0.06 | Upgrade |
EPS Growth | 5.72% | 3.85% | -10.35% | 16.00% | 733.33% | -91.18% | Upgrade |
Free Cash Flow | 302.05 | 561.45 | 168.44 | 371.84 | 702.48 | 731.86 | Upgrade |
Free Cash Flow Per Share | 0.27 | 0.50 | 0.15 | 0.34 | 0.66 | 0.72 | Upgrade |
Dividend Per Share | 0.500 | 0.500 | 0.500 | 0.500 | 0.400 | - | Upgrade |
Dividend Growth | - | - | - | 25.00% | - | - | Upgrade |
Gross Margin | 74.06% | 71.64% | 68.34% | 71.26% | 73.47% | 69.04% | Upgrade |
Operating Margin | 16.60% | 17.05% | 16.81% | 16.24% | 16.49% | 11.19% | Upgrade |
Profit Margin | 15.18% | 14.99% | 17.24% | 18.30% | 17.45% | 2.22% | Upgrade |
Free Cash Flow Margin | 7.37% | 13.99% | 5.00% | 10.68% | 22.97% | 26.72% | Upgrade |
EBITDA | 1,055 | 1,045 | 893.22 | 873.67 | 798.4 | 552.33 | Upgrade |
EBITDA Margin | 25.73% | 26.03% | 26.54% | 25.09% | 26.11% | 20.17% | Upgrade |
D&A For EBITDA | 374.26 | 360.6 | 327.4 | 308.09 | 294.1 | 246.03 | Upgrade |
EBIT | 680.87 | 683.93 | 565.82 | 565.58 | 504.3 | 306.3 | Upgrade |
EBIT Margin | 16.60% | 17.05% | 16.81% | 16.24% | 16.49% | 11.19% | Upgrade |
Effective Tax Rate | 2.46% | 4.33% | 9.50% | 11.12% | 11.92% | 11.64% | Upgrade |
Revenue as Reported | 4,101 | 4,012 | 3,365 | 3,482 | 3,058 | 2,739 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.